Nothing Special   »   [go: up one dir, main page]

Papathanassoglou et al., 2000 - Google Patents

Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? A review and a theoretical framework

Papathanassoglou et al., 2000

Document ID
12051841679540941249
Author
Papathanassoglou E
Moynihan J
Ackerman M
Publication year
Publication venue
Critical care medicine

External Links

Snippet

Objectives: To critically review the current understanding of the pathophysiologic events leading to the development of secondary multiple organ dysfunction (MODS) in critical illness and to examine the role of apoptosis (programmed cell death) as a mechanism …
Continue reading at journals.lww.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Papathanassoglou et al. Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? A review and a theoretical framework
Nigam et al. The systems biology of uric acid transporters: the role of remote sensing and signaling
Burne-Taney et al. Acute renal failure after whole body ischemia is characterized by inflammation and T cell-mediated injury
Dinarello et al. Role of IL-1β in type 2 diabetes
Meldrum et al. TNF-α-dependent bilateral renal injury is induced by unilateral renal ischemia-reperfusion
Ren et al. IL-22 is involved in liver regeneration after hepatectomy
Hensler et al. Association between injury pattern of patients with multiple injuries and circulating levels of soluble tumor necrosis factor receptors, interleukin-6 and interleukin-10, and polymorphonuclear neutrophil elastase
Vallet et al. Endothelial cell dysfunction and coagulation
Chow et al. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice
Tsujimoto et al. Neutrophil elastase, MIP-2, and TLR-4 expression during human and experimental sepsis
Yang et al. Blockage of JAK/STAT signalling attenuates renal ischaemia-reperfusion injury in rats
Zou et al. The protective effects of PUGNAc on cardiac function after trauma-hemorrhage are mediated via increased protein O-GlcNAc levels
Day et al. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction
Liu et al. Renoprotective and immunomodulatory effects of GDF15 following AKI invoked by ischemia-reperfusion injury
Sass et al. Cooperative effect of biliverdin and carbon monoxide on survival of mice in immune-mediated liver injury
Bucher et al. Nitric oxide-dependent down-regulation of angiotensin II type 2 receptors during experimental sepsis
Simms et al. Activated macrophages decrease rat cardiac myocyte contractility: importance of ICAM-1-dependent adhesion
Tonnus et al. The clinical relevance of necroinflammation—highlighting the importance of acute kidney injury and the adrenal glands
Bylander et al. Targeted disruption of the meprin metalloproteinase β gene protects against renal ischemia-reperfusion injury in mice
Vodovotz et al. Augmenter of liver regeneration (ALR) is a novel biomarker of hepatocellular stress/inflammation: in vitro, in vivo and in silico studies
Jacobi et al. Priming of polymorphonuclear leukocytes: a culprit in the initiation of endothelial cell injury
Krams et al. HUMAN HEPATOCYTES PRODUCE AN ISOFORM OF FAS THAT INHIBITS APOPTOSIS1
Hocher et al. Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension
Xu et al. Eosinophils protect against Acetaminophen‐induced liver injury through cyclooxygenase‐mediated IL‐4/IL‐13 production
Sur et al. FcER1: a novel molecule implicated in the progression of human diabetic kidney disease